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■ Abstract
Background: Allergic rhinoconjunctivitis induced by pollen is a highly prevalent chronic infl ammatory disease in Europe. Parietaria judaica 
is a frequent trigger in the Mediterranean area. The function of regulatory T cells (Treg cells) in allergy has recently been investigated, 
but further data are necessary to better understand their role and to fi nd new strategies to treat allergic diseases such as allergic 
rhinoconjunctivitis.
Objective: To characterize gene expression of HLA-DR+ or HLA-DR– on peripheral CD4+/CD25++/CD127low Treg cells in patients with 
allergy. 
Methods: Peripheral Treg cells (CD4+/CD25++/CD127low) were quantifi ed using fl ow cytometry and sorted according to HLA-DR expression 
during the pollen season in patients with allergic rhinoconjunctivitis caused by P judaica. The results were compared with those of nonatopic 
controls. Expression of associated cytokines and their receptors was measured using quantitative reverse transcription-polymerase chain 
reaction after extraction of mRNA in sorted populations. 
Results: During the pollen season, no signifi cant differences were observed between allergic patients with rhinoconjunctivitis and healthy 
controls in terms of the absolute number or the percentage of Treg cells in peripheral blood. All patients had a higher number/percentage 
of HLA-DR– Treg cells than HLA-DR+ Treg cells. In both groups we found high levels of FOXP3 mRNA expression. Despite being lower in 
number, HLA-DR+ Treg cells presented higher expression of CD28, PRF1, GZMB, and FASL than HLA-DR– Treg cells. 
Conclusions: The most relevant results obtained suggest that HLA-DR+ Treg cells tend to present higher gene expression of molecules 
associated with contact-dependent cell activation and cytotoxicity.
Key words: Gene expression. Regulatory T cell (Treg). Rhinoconjunctivitis. Parietaria judaica allergy.
■ Resumen
Antecedentes: La rinoconjuntivitis alérgica inducida por el polen es una enfermedad infl amatoria crónica muy frecuente en Europa. La 
especie Parietaria judaica es un desencadenante común en la región mediterránea. Recientemente se ha investigado la función de los 
linfocitos T reguladores (linfocitos Treg) en la alergia. Sin embargo, son necesarios más datos para comprender mejor dicha función y 
encontrar nuevas estrategias para tratar enfermedades alérgicas como la rinoconjuntivitis alérgica.
Objetivo: Caracterizar la expresión de HLA-DR+ o HLA-DR– en linfocitos Treg periféricos CD4+/CD25++/CD127bajo en pacientes alérgicos. 
Métodos: Se cuantifi caron linfocitos Treg periféricos (CD4+/CD25++/CD127bajo) mediante citometría de fl ujo y se clasifi caron según la expresión 
de HLA-DR durante la estación polínica en pacientes con rinoconjuntivitis alérgica causada por P. judaica. Los resultados se compararon 
con los de controles no atópicos. En ambas poblaciones se determinó la expresión de las citocinas asociadas y sus receptores mediante 
transcripción inversa y reacción en cadena de la polimerasa cuantitativa. 
Resultados: Durante la estación polínica no se observaron diferencias signifi cativas entre los pacientes alérgicos con rinoconjuntivitis y los 
controles sanos en términos de número absoluto o porcentaje de linfocitos Treg en sangre periférica. Todos los pacientes presentaron un 
número/porcentaje de linfocitos Treg HLA-DR– superior al de linfocitos Treg HLA-DR+. En ambos grupos se registraron niveles de expresión 
elevados del ARNm de FOXP3. A pesar de ser inferiores en número, los linfocitos Treg HLA-DR+ presentaron una mayor expresión de CD28, 
PRF1, GZMB y FASL que los linfocitos Treg HLA-DR–. 
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Introduction
Allergic diseases are chronic disorders characterized 
by hyperresponsiveness to allergens (eg, airborne 
particles) involving recruitment and activation of immune 
and inflammatory cells [1]. Atopy and allergic diseases 
can result from impaired inhibition of allergen-specific 
helper T cell (T
H
)–type responses by regulatory T cells 
(Treg), a major subset of immune cells [2,3]. 
Modulation of infl ammatory diseases depends on Treg 
cells, as these maintain immune self-tolerance in the periphery, 
thus limiting inflammatory responses [4,5]. These cells 
actively and dominantly suppress both activation and effective 
functioning of autoreactive T cells, which evade other tolerance 





cells [6]. At the cellular level, several types of CD4+ Treg cells 
have been associated with regulatory function in allergy, in 
which peripheral T lymphocytes are characterized by higher 
expression of activation markers, such as the interleukin (IL) 
2 receptor α chain (CD25) [5]. CD25 is not only a marker for 
CD4+-activated T cells, but it is also present in Treg cells. 
At gene level, FOXP3, a member of the forkhead box 
protein family, identifi es the natural Treg population, and 
seems to play a crucial role in the differentiation of Treg cells 
from antigen-naïve T cells. Furthermore, FOXP3 is believed 
to be a master regulator of the development and function of 
CD25+ Treg cells [5]. 
Immune responses in both healthy and allergic individuals 
appear to result from the reciprocal modulation of allergen-




2 cells. Activated T
H
2 cells regulate 
production of immunoglobulin (Ig) E and recruit infl ammatory 
cells by releasing a wide range of cytokines such as IL-4, IL-
5, and IL-13. Interestingly, the suppression of T
H
2 cells from 
effector cells by CD4+CD25++ Treg cells has been described 
in atopic individuals, although it is not effective during the 
pollen season [2,7,8]. 
Most patients with allergic rhinitis classify their disease 
as severe. Allergic rhinitis can lead to impairment of daily 
activities, quality of sleep, and productivity, with the 
consequent social and economic costs [9,10]. The disease is 
defi ned as a symptomatic disorder induced by an IgE-mediated 
infl ammation of the nasal mucosa after exposure to an allergen 
[11]. Symptoms are triggered by the interaction of the allergen 
with IgE, which binds to mast cells in the nasal mucosa or to 
circulating basophils. Plant pollen is one of the most prevalent 
allergens [12], and in the Mediterranean area and the temperate 
climates of Central and Eastern Europe, the highly allergenic 
Parietaria pollen is a frequent cause of pollinosis [13-16]. 
Characterization of the cellular and genetic events 
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Conclusiones: Los resultados más relevantes obtenidos parecen indicar que los linfocitos Treg HLA-DR+ presentan una mayor expresión 
génica de moléculas asociada a la activación y la citotoxicidad de células dependientes del contacto.
Palabras clave: Expresión génica. Linfocito T regulador (Treg). Rinoconjuntivitis. Alergia a Parietaria judaica.
involved in Treg cell function is important in order to 
understand and treat allergic diseases, such as allergic 
rhinoconjunctivitis. Treg cells expressing HLA-DR induce 
early contact-dependent suppression and cytotoxicity, and 
are involved in downregulation of different inflammatory 
responses [17].
We investigated the role of Treg cells (CD4+/CD25++/CD127low) 
and gene expression profi le after sorting HLA-DR+ and HLA-DR– 
Treg cells from the blood of patients with pollen allergy during pollen 
season and demonstrated mRNA differences in a list of transcripts 
of interest. These Treg cells were collected from patients with 
allergic rhinoconjunctivitis induced by Parietaria judaica and 
compared with nonatopic controls. Shevach et al [18] identifi ed 
natural Treg cells that were not activated by antigen, but by 
major histocompatibility complex (MHC) class II self-peptide 
and cytokines released by activated effector cells. In our study 
we analyzed the cytokines involved in the effector functions 
of T cells (eg, IL-13, IL-4, IL-2, interferon [INF] γ and IL-6) 
and membrane receptors (CCR7, CD28, and CXCR3) that 
facilitate cell adhesion and migration. Natural Treg cells can 
also differentiate into potent granzyme B–dependent cells, 
and into partially perforin-independent cytotoxic cells that 
can kill antigen-presenting B cells [18]. We also analyzed the 
expression of cytokines involved in apoptosis and cytotoxicity, 
namely, Fas ligand, granzyme B, and perforin-1. Finally, 
expression of IL-10, INF-γ and transforming growth factor 
(TGF) ß1 was measured, although the role of these cytokines 
in regulatory function is not dependent on cellular contact. 
Methods
Participants
This study was approved by the Coimbra University 
Hospitals Ethics Board. Ten consecutive female patients with 
rhinoconjunctivitis caused by exposure to P judaica were 
enrolled after giving their oral informed consent (Group I). 
Mean (SD) age was 33 (13) years (range, 17-62). Diagnosis 
and classifi cation of rhinitis were based on the Allergic Rhinitis 
and its Impact on Asthma (ARIA) guidelines [19]. 
No patient had persistent asthma according to the Global 
Initiative for Asthma (GINA) Guidelines [20]. Smokers and 
patients with recent (last 6 weeks) infectious, autoimmune, 
or neoplastic diseases were excluded. Patients treated with 
specifi c immunotherapy were also excluded.
Eight healthy nonallergic volunteers with a mean age of 
29 (6) years (range, 22-40) were included as controls (Group 
II). The presence of rhinitis in group II was excluded using a 
detailed clinical questionnaire.
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Skin Testing
All participants underwent skin prick tests (SPT) to 
29 aeroallergens (ALK-ABELLO, Madrid, Spain) using 
disposable 1-mm–tip sterile lancets (Stallergènes, Antony, 
France), as follows: Corylus avellana, Alnus cordata, Betula 
verrucosa, Platanus acerifolia, Cupressus arizonica, Graminea 
mixture, Olea europaea, Artemisia vulgaris, Ambrosia elatior, 
Alternaria tenuis, Cladosporium herbarum, Aspergillus 
fumigatus, Parietaria judaica, Canis familiaris, Felis catus, 
Dermatophagoides pteronyssinus, Dermatophagoides farinae, 
Blatella germanica, Lepidoglyphus destructor, Tyrophagus 
putrescenciae, Quercus rober, Salix alba, Pinus radiata, 
Castanea sativa, Chenopodium album, Plantago lanceolata, 
Rumex azoricus, Tilia cordata, and Populus alba. Histamine 
dihydrochloride was used as a positive control (10 mg/mL) 
and 0.9% saline solution as a negative control. The SPT results 
were recorded 15 minutes after the start of the test and were 
considered positive if the wheal and fl are diameter of each 
allergen was at least 3 mm greater than that of the negative 
control.
All patients included had a positive SPT result to P judaica 
pollen and their clinical symptoms were typical of patients who 
are allergic to this pollen. The study was performed during the 
2007 grass-pollen season (April and May). 
Determination of Total and Specifi c IgE 
Peripheral blood was withdrawn from the vein of the 
forearm of all individuals and placed into 2 tubes with 
sodium-heparin and into 1 Paxgene RNA tube (PreAnalytix, 
Hombrechtikon, Switzerland).
The differential blood cell count was performed using the 
Coulter Act Diff 2 hematological analyzer (Beckman Coulter, 
Fullerton, California, USA).
Quantitative determination of total serum IgE was 
performed using nephelometry. Total IgE concentration 
(IU/mL) was determined by comparing the results with the 
calibrators provided.
Serum specifi c IgE to P judaica was determined using 
the ImmunoCAP fluorescence enzyme immunoassay 
technique (Phadia, Uppsala, Sweden). To evaluate the test 
results, the response from the patient samples was converted 
to concentrations using a calibration curve. The range of 
measurements was 0.35 to 100 kU
A
/L. The allergic patients 
selected had values higher than 3.51 kU
A
/L (Class III) as part 
of their inclusion criteria.
Basophil Activation Test 
The basophil activation test (BAT) is based on fl ow-
cytometric quantifi cation of the allergen-induced upregulation 
of the granule-associated marker CD63 or gp53 in peripheral 
basophils. Two tubes were prepared with 100 µL of blood 
plus 100 µL of stimulation buffer with or without 0.05 mg of 
P judaica allergen [20 mg/mL]. Cells were incubated for 40 
minutes at 37ºC. The degranulation process was stopped by 
dipping the tubes in ice for 5 minutes. Peripheral blood was 
incubated with the fluorochrome-conjugated monoclonal 
antibodies–anti-CD63 fl uorescein isothiocyanate (FITC), anti-
CD123 phycoerythrin (PE), anti-HLA-DR mixture peridinin 
chlorophyll protein (PerCP) (H5C6/9F5/L243 [G46-6]; BD 
Biosciences, San Jose, California, USA) and kept in the dark 
and on ice for 15 minutes. Erythrocytes were lysed with 2 mL 
of FACS Lysing Solution (BD Biosciences) for 10 minutes. 
Cells were washed twice with phosphate-buffered saline 
(PBS 1x, Biochrom, AG, Berlin, Germany). The percentage 
of degranulated cells was measured using fl ow cytometry 
(FACSCalibur, BD Biosciences). The test was considered 
positive if the degranulation percentage was higher than 5% 
and the ratio of stimulated to nonstimulated cells was higher 
than 2. 
Regulatory T cell Gene Expression
Isolation of regulatory T cells: Peripheral blood containing 
the anticoagulant sodium heparin was centrifuged at 1500 rpm for 
5 minutes at room temperature. The buffy coat was recovered 






The samples were incubated to identify Treg cells, as 
follows: anti-CD127 in PE (hIL-7R-M21; BD Biosciences, 
Pharmingen, San Diego, California, USA); anti-CD25 in FITC 
(M-A251; BD Bioscience Pharmingen); anti-CD4 in PerCP 
(JK3; BD Biosciences); and anti-HLA-DR in allophycocyanin 
(L243 [G46-6]; BD Biosciences) for 30 minutes at room 
temperature and washed twice with PBS 1x (Biochrom, AG) 
and centrifuged. 
CD4+/CD25++/CD127low/HLA-DR+ and CD4+/CD25++/
CD127low/HLA-DR– cells were isolated using fl uorescence-
activated cell sorting (BD FACSAria,  BD Biosciences) 
and separated according to HLA-DR expression. Cells were 
collected in individual polymerase chain reaction (PCR) tubes 
with 5 µL of PBS treated with 0.1% diethyl pyrocarbonate and 
cooled to –80ºC.
Treg cells were quantified using a double-platform 
approach (hematological analyzer and FACS).
Reverse transcription: Cells isolated by FACS were 
lysed, cooled to –80ºC, heated to 65ºC for 2 minutes, and 
cooled again to 4ºC before reverse transcription. Quantitative 
reverse transcription-PCR (qRT-PCR) was performed using 
the SuperScript III First-Strand Synthesis System (Invitrogen, 
Carlsbad, California, USA) according to the manufacturer’s 
instructions. The reactions were performed in a thermocycler 
(MyCycler, Biorad, Hercules, California, USA) using the 
following steps: 10 minutes at 25ºC, 50 minutes at 50ºC, 5 
minutes at 85ºC, and a fi nal hold at 4ºC. The cDNAs were 
stored at –80ºC.
Real-time PCR: PCR assays were performed in a 7900 
HT Sequence Detection System (Applied Biosystems, Foster 
City, California, USA). Prepared cDNA was amplifi ed using 
1XQuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, 
Germany) on a 96-well PCR plate following the manufacturer’s 
recommendations. qRT-PCR was performed using specifi c 
QuantiTect Primer Assays (Qiagen) for the following genes: 
CCR7 (QT00045507), CD28 (QT00001267), CXCR3 
(QT00213493), FASL (QT00001281), FOXP3 (QT00048286), 
GZMB (QT01001875), HLADRB1 (QT00090993), IL10 
(QT00041685), IL13 (QT00000511), IL2 (QT00015435), IL4 
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(QT00012565), IL6 (QT00083720), IFNG (QT00000525), 
PRF1 (QT00199955), TGFB1 (QT00000728), TNFA 
(QT00029162), and TNFRSF1A (QT00216993). Quantifi cation 
of gene expression was preceded by a normalization step 
using the geNorm Housekeeping Gene Selection kit for 
Rattus norvegicus (Primer Design, Southampton, United 
Kingdom) and geNorm software (Ghent University Hospital, 
Center for Medical Genetics, Ghent, Belgium) to select 
optimal housekeeping genes for this study [21]. Relative 
quantifi cation was normalized with the housekeeping genes 
ACTB (QT01680476) and GAPDH (QT01192646) for both 
HLA-DR+ and HLA DR– Treg cells.
Real-time PCR cycle conditions were as follows: an initial 
activation stage of 15 minutes at 95ºC followed by a second 
stage comprising 15 seconds at 94ºC, 30 seconds at 55ºC, and 
30 seconds at 72ºC (with 50 repeats).
Calculation of results: mRNA expression was analyzed 
through the relative quantifi cation of mRNA from HLA-DR+ 
Treg cells and mRNA from HLA-DR– Treg cells using the 
comparative ∆∆CT method described by Livak et al [22].
Statistical Analysis
The statistical analysis was performed using SPSS 15.0. 
A Mann-Whitney test was applied to evaluate differences 
between groups. A P value of less than .05 was considered 
statistically signifi cant. 
Results
Age, sex, serum total IgE, serum specifi c IgE to P judaica, 
eosinophil count, and the BAT results are summarized in Table 1. 
All individuals enrolled in the study were female. Allergic 
patients reported the mean age for the onset of symptoms to 
be 11 (7) years. 
Most patients with rhinoconjunctivitis had higher total 
serum IgE levels (8 out of 10) (P=.02) and peripheral 
eosinophil counts (P=.13) than nonallergic patients. Allergic 
patients had positive SPT results to P judaica and at least 1 of 
the other allergens tested.
Table 1. Characteristics of the Study Groupsa 
  Patients (n=10)  Controls (n=8) P Value    
Sex
(Female/Male)  10/0 8/0
Age, y  33 (13) 29 (6)b >.05
Serum total IgE, kU
A
/L 317.8 (293.4) 30.7 (15.2)c .02
Serum specifi c IgE to 
Parietaria judaica, kU
A
/L 31.1 (23.2) <0.35c .02
Eosinophils, cells/µL 407.1 (337.4) 166.7 (81.7)b >.05
BAT  Positive Negative
Abbreviations: BAT, basophil activation test; Ig, Immunoglobulin. 
aData are expressed as mean (SD).
bP value is nonsignifi cant.
cP<.05.
The number and the percentage of total leukocytes, lymphocytes, 
CD4+ lymphocytes, Treg cells (CD4+CD25++CD127low), HLA-
DR+ Treg cells, and HLA-DR– Treg cells were calculated using 
the double-platform approach (hematological analyzer and 
FACS) are presented in Table 2.
No signifi cant differences were observed between the 
allergic and the nonallergic group for number (P=.63) or 
percentage (P=.25) of Treg cells from peripheral blood (Table 2 
and Figure 1).
The Treg cells identifi ed by CD4+CD25++CD127low were also 
analyzed according to HLA-DR expression, revealing 4 groups: 
HLA-DR+ Treg cells from allergic patients; HLA-DR– Treg cells 
from allergic patients; HLA-DR+ Treg cells from controls 
and HLA-DR– Treg cells from controls. All participants had 
a smaller number or percentage of HLA-DR+ Treg cells. 
We could not fi nd signifi cant differences in the number or 
percentage of these cells between allergic and nonallergic 
individuals. Therefore, the difference observed in the 
percentage of HLA-DR+ Treg cells between the 2 groups was 
too close to be statistically signifi cant (P=.08) (Figure 2).
mRNA expression of HLA-DR+ and HLA-DR– Treg cell 
subpopulations in allergic and nonallergic individuals is presented 
in Figure 3 through the relative quantifi cation of 2–∆CT(log) mRNA 
between the differences in expression of the gene of interest and 
the housekeeping gene (ACTB and GAPDH).
No signifi cant differences in gene expression were found 
between the 4 groups. Nevertheless, relative gene expression 
between allergic patients and controls tended to be different. 
The Treg cells of allergic patients showed higher expression 
of FASL, GZMB, PRF1, CCR7, CXCR3, TGFB, TNFA, and 
IL13 and lower expression of IL2 and IFNG. Expression of 
FOXP3, CD28, IL10, and IL4 was very similar in patients 
and in controls. FOXP3 and CD28 showed high levels and 
IL10 and IL4 showed low levels in relation to endogenous 
gene expression. 
Our results are presented in Figure 4 as a relative 
quantification (arbitrary units), namely, the average fold 
increase in gene expression in HLA-DR+ Treg cells compared 
with the average fold increase in gene expression in HLA-DR– 
Treg cells in allergic and nonallergic individuals.
Gene Profi le of HLA-DR+/DR– Treg Cells in Allergy
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Table 2. Complete Blood Count Performed Using a Double-Platform Approach (Hematological Analyzer and FACS)a
  Patients Controls P Value    
Leukocytes, cells/µL 7667 (2848) 7387 (1423)b >.05
Lymphocytes
   Cells/µL  2296 (1728) 2634 (1110)b
   % Leukocytes 29.6 (15.2) 34.8 (11.5) >.05
Lymphocytes T-CD4+
   Cells/µL  881 (627) 1268 (636)b
   % Lymphocytes 38.6 (8.5 48.1 (8.5) >.05
Treg cells
   (CD4+CD25++CD127low)
    Cells/µL  70 (54) 86 (56)b
   % Lymphocytes 8.4 (2.6) 6.8 (3.99) >.05
Treg cells HLA-DR+
(CD4+CD25++CD127lowDR+)
   Cells/µL  18 (14) 15 (11)b
   % Treg cells  26.8 (5.0) 18.3 (9.5) >.05
Treg cells HLA-DR–
(CD4+CD25++CD127lowDR–)
   Cells/µL  51 (399) 70 (48)b
   % Treg cells  72.5 (4.7) 80.6 (8.9) >.05
Abbreviation: Treg, regulatory T cells. 
aData are expressed as mean (SD).
bP value is nonsignifi cant.
The HLA-DR+ Treg cells from the control group presented 
higher expression values than HLA-DR– Treg cells in most 
of the variables studied. The exceptions were CXCR3 and 
PRF1. In the allergic group, every mRNA expression value of 
HLA-DR+ Treg cells was higher than those of HLA-DR– Treg 
cells, despite HLA-DR+ Treg cells being lower in number. The 
difference in gene expression between HLA-DR+ and HLA-
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Figure 2. Distribution of HLA-DR+ regulatory T cells in allergic and nonallergic individuals.
Figure 3. Gene expression profi le from HLA-DR+ Treg cells and HLA-DR– Treg cells in allergic and nonallergic (controls) individuals.
The values above represent the relative quantifi cation of 2–∆CT(log) mRNA between the different expression of the gene of interest and the housekeeping 
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Figure 4. Gene expression profi le from Treg cells in allergic and nonallergic (controls) individuals. The values above represent the relative quantifi cation 
(arbitrary units): the average fold increase in gene expression from HLA-DR+ Treg cells in relation to the average fold increase in gene expression from 
HLA-DR– Treg cells in allergic and nonallergic individuals.
Discussion
This study was carried out to evaluate expression of 
HLA-DR in CD4+/CD25++/CD127low Treg cells in a chronic 
infl ammatory disease such as allergic rhinoconjunctivitis. 
Circulating human CD4 cells can express MHC-II, a 
marker of activated cells that reduces T-cell responsiveness to 
new antigens [23]. In circulating CD4+CD25++ T cells, MHC-II 
expression reveals functionally distinct Treg populations [17], 
which show suppression activity on contact with the membrane 
and downregulate different infl ammatory responses. This cell 
population also participates in homeostatic maintenance of 
Treg in vivo by presenting self-antigens to other Treg cells. 
In contrast, the HLA-DR– Treg population fi rst induces a T
H
2 
immune response through release of soluble mediators and later 
activates a FOXP3-associated contact-dependent suppression 
mechanism. 
We analyzed the differences in mRNA expression between 
HLA-DR+ and HLA-DR– Treg subpopulations.
As expected, patients had high levels of total IgE. In 
addition, BAT confi rmed in vitro that P judaica pollen was an 
allergen in the allergic individuals studied. FOXP3 expression 
was high in all groups, and this result was consistent with our 
accurate Treg selection using FACS. 
The percentage of Treg cells was within the normal range, 
from 5% to 10% of CD4+ T cells in peripheral blood [6]; 
no statistical differences were found between patients and 
controls. This may indicate that the number of Treg is not such 
an important factor in the disease process. Grindebacke et al [8] 
found that the number of CD25+ Treg cells in blood and their 
ability to suppress allergen-specifi c proliferative responses 
were similar in allergic patients and healthy controls outside 
the pollen season, although suppressive activity diminished 
during the pollen season. It seems unlikely that there was 
a complete dysfunction of the Treg repertoire targeting the 
antigen repertoire. Other authors, however, have found that 
allergic patients have fewer Treg cells and that therapeutic 
approaches such as specifi c immunotherapy can re-establish 
cells with suppressive potential [24]. 
All the participants had a smaller percentage of HLA-
DR+ Treg cells–between 20% and 30% of the CD4+CD25++ 
regulatory population–in much the same proportion reported 
by others authors [17]. Data from the control group varied 
widely. There were no signifi cant differences in the number 
or percentage of these cells between patients and controls, 
although a trend toward statistical signifi cance was observed 
(P=.08) in the percentage of HLA-DR+/Treg cells in allergic 
patients in relation to controls. As HLA-DR+ cells are activated 
in order to exert contact-dependent suppression, their higher 
percentage in allergic patients could represent a controlled 
response to the allergic stimulus. In addition, the difference in 
gene expression between HLA-DR+ and HLA-DR– Treg cells 
was not statistically signifi cant. This could be explained by 
the low number of study patients who also had highly variable 
results for relative gene expression. Nevertheless, relative gene 
expression between the 2 groups tended to be different.
In accordance with contact-dependent suppression activity 
through HLA-DR, both allergic and nonallergic individuals 
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had high levels and similar amounts of costimulatory CD28 
expression. After antigen exposure, interactions between CD28 
and CD80 activate T lymphocytes and induce proliferation and 
differentiation of effector T cells [25]. When CD28 monoclonal 
antibody is added, Treg seem to expand without T-cell receptor 
enrolment or cross-linking. 
Chemokine receptors play an essential role in leukocyte 
migration and chemotaxis. There is some controversy over 
whether these receptors can function as phenotypic markers 
in certain cell subsets: the chemokine receptor profi le can be 
changed without a concomitant change in cytokine profi le [26]. 
CXCR3 has been reported to be a T
H
1 marker and is abundant 
on memory T lymphocytes [27]. This homing receptor gene, 
which has also been associated with entry and permanence of T 
cells in lymph nodes, showed higher expression in all the individuals 
studied, although with a reduced ratio among HLA-DR+ cells [28]. 
The lymphoid-homing chemokine receptor gene CCR7 is not 
expressed as much as CXCR3, and higher levels of CCR7 were 
found in patients than in controls. There is evidence that CCR7 
mediates Treg migration to the paracortical areas of lymph nodes 
under steady-state conditions, although CCR7-independent 
migration through high endothelial venules also takes place in 
the medulla [29].
Analysis of mRNA by qRT-PCR demonstrated different 
cytokine gene expression profiles in HLA-DR+ and 
HLA-DR– Treg cells (CD4+/CD25++/CD127low). We observed 
low levels of mRNA expression of cytokines IL-2 and IL-6 
in relation to endogenous gene expression, suggesting less 
important infl ammatory activity in Treg cells. Besides being 
responsible for the differentiation of T cells into cytotoxic cells, 
and B cells into plasma cells, IL-6 contributes to the development 
of T
H
17 cells and inhibits Treg cells [30]. In our study, mRNA 
expression of IL-6 was more evident in HLA-DR+ Treg cells 
than in HLA-DR– Treg cells in the patients. The same results 
were observed for IL-2 mRNA expression.
We also found low levels of expression of IL-10 and IL-4 
with similar patterns in both patients and controls. Curiously, 
IL-13 and TGFß mRNA expression seem to be more associated 
with HLA-DR+ Treg cells.
The patients’ Treg cells tended to have more transcripts 
involved in cytotoxic activity. Their HLA-DR+ Treg cells 
overexpressed PRF1 and GZMB mRNA. Cytolytic proteins 
stored in secretor granules (eg, perforin) from cytotoxic 
lymphocytes and NK cells, are crucial for immune surveillance 
and homeostasis. Perforin synergizes with pro-apoptotic 
serine proteases, such as granzymes, thus targeting the cell 
and inducing apoptosis. Granzyme B is the most powerful 
pro-apoptotic member of the granzyme family [31].
Moreover, apoptotic FasL (a TNF family member that 
is involved in the selection of thymocytes and cytotoxicity 
mediated by T cells and NK cells) also had higher mRNA 
levels in activated HLA-DR+ Treg cells in patients. It seems that 
FasL may play a role as an accessory/costimulatory molecule 
sending a retrograde transduction signal into FasL-expressing 
cells [32]. In our study, both FasL mechanisms probably 
played a role in patients, whose high mRNA levels of FASL 
in HLA-DR+ Treg cells associated with the high mRNA 
expression of PRF1 and GZMB could promote apoptosis of 
autoreactive cells and selected cells in the allergic response.
The methods used to identify the different expression 
profi les could not fully reproduce all the mRNA expressed 
by the cells studied. This could be due to the short life span 
of mRNA and the fact that we only examined peripheral 
blood cells at a specifi c point in time. There are unlikely to be 
important immunological differences between groups. What 
is likely is that allergic and nonallergic individuals display 
different functions of their allergen-specifi c Treg cells during 
the spring allergy season. We think that our results have brought 
some new insights to the study of immune regulation of Treg 
cells by cell contact activation.
In summary, we found no evidence that a numerical 
difference in Treg cells in blood exists between adult patients 
with allergic rhinoconjunctivitis and healthy controls during 
the pollen season. The most relevant results obtained suggest 
that HLA-DR+ Treg cells tend to present higher gene expression 
of molecules associated with contact-dependent cell activation 
and cytotoxicity. 
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